How much does intravenous Remdesivir (Veklury) shorten recovery for hospitalized high-risk patients?

Roughly five days

Remdesivir, administered intravenously and often referred to by its trade name Veklury, is an antiviral option specifically utilized in clinical settings for individuals who have progressed to a stage requiring hospitalization or those deemed high-risk enough to warrant such aggressive intervention. Clinical evidence supports its role in managing the progression of the disease in these more severe scenarios. For patients receiving this specific treatment intravenously, studies have indicated a tangible benefit in the timeline of their recuperation, demonstrating an ability to shorten the overall recovery period by a measure of roughly five days compared to those not receiving this intervention.